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Abstract
Background
Guidelines recommend stepping down asthma treatment to the minimum effective dose to
achieve symptom control, prevent adverse side effects, and reduce costs. Limited data exist
on asthma prescription patterns in a real-world setting. We aimed to evaluate the appropri-
ateness of doses prescribed to a UK general asthma population and assess whether step-
ping down medication increased exacerbations or reliever use, as well as its impact on
costs.
Methods and findings
We used nationwide UK primary care medical records, 2001–2017, to identify 508,459 adult
asthma patients managed with preventer medication. Prescriptions of higher-level medica-
tion: medium/high-dose inhaled corticosteroids (ICSs) or ICSs + add-on medication (long-
acting β2-agonist [LABA], leukotriene receptor antagonist [LTRA], theophylline, or long-act-
ing muscarinic antagonist [LAMA]) steadily increased over time (2001 = 49.8%, 2017 =
68.3%). Of those prescribed their first preventer, one-third were prescribed a higher-level
medication, of whom half had no reliever prescription or exacerbation in the year prior. Of
patients first prescribed ICSs + 1 add-on, 70.4% remained on the same medication during a
mean follow-up of 6.6 years. Of those prescribed medium/high-dose ICSs as their first pre-
venter, 13.0% already had documented diabetes, cataracts, glaucoma, or osteopenia/oste-
oporosis. A cohort of 125,341 patients were drawn to assess the impact of stepping down
medication: mean age 50.4 years, 39.4% males, 39,881 stepped down. Exposed patients
were stepped down by dropping their LABAs or another add-on or by halving their ICS dose
(halving their mean-daily dose or their inhaler dose). The primary and secondary outcomes
were, respectively, exacerbations and an increase in reliever prescriptions. Multivariable
regression was used to assess outcomes and determine the prognostic factors for initiating
stepdown. There was no increased exacerbation risk for each possible medication step-
down (adjusted hazard ratio, 95% CI, p-value: ICS inhaler dose = 0.86, 0.77–0.93, p <
0.001; ICS mean daily = 0.80, 0.74–0.87, p < 0.001; LABA = 1.01, 0.92–1.11, p = 0.87, other
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add-on = 1.00, 0.91–1.09, p = 0.79) and no increase in reliever prescriptions (adjusted odds
ratio, 95% CI, p-value: ICS inhaler dose = 0.99, 0.98–1.00, p = 0.59; ICS mean daily = 0.78,
0.76–0.79, p < 0.001; LABA = 0.83, 0.82–0.85, p < 0.001; other add-on = 0.86, 0.85–0.87, p
< 0.001). Prognostic factors to initiate stepdown included medication burden, but not medi-
cation side effects. National Health Service (NHS) indicative prices were used for cost esti-
mates. Stepping down medication, either LABAs or ICSs, could save annually around
£17,000,000 or £8,600,000, respectively. Study limitations include the possibility that pre-
scribed medication may not have been dispensed or adhered to and the reason for step-
down was not documented.
Conclusion
In this UK study, we observed that asthma patients were increasingly prescribed higher lev-
els of treatment, often without clear clinical indication for such high doses. Stepping down
medication did not adversely affect outcomes and was associated with substantial cost
savings.
Author summary
Why was this study done?
• There is a growing interest in rationalising medicines through deprescribing.
• Specifically, asthma guidelines strongly recommend stepping down asthma medication
in stable patients to reduce the risk of side effects from long-term use, in particular from
inhaled corticosteroid use.
• Guideline recommendations are based on trials, comparing stable patients that were
stepped down to those that were not, but these trials were small in size, had short fol-
low-up periods, and may not represent what happens in day-to-day clinical practice.
What did the researchers do and find?
• We studied adult asthma patients from across the UK, using primary care electronic
medical records, and found prescriptions of higher-dose asthma medication have
steadily increased between 2001 and 2017.
• Stepping down medication occurred infrequently but did not increase asthma exacerba-
tions or the use of reliever medication; patients at risk of medication side effects were
not preferentially stepped down.
• This clinical practice was shown to have considerable cost savings if carried out in stable
asthma patients.
What do these findings mean?
• There is an increasing tendency to prescribe higher-dose, expensive asthma
medications.
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medication adverse effects.
Introduction
Over the past 4 decades, the use of inhaled corticosteroids (ICSs) and, subsequently, long-act-
ing β2-agonists (LABAs) have resulted in extraordinary improvements in outcomes for people
with asthma [1,2]. Since the mid-1990s, asthma guidelines and strategies (including Global Ini-
tiative for Asthma [GINA], National Asthma Education and Prevention Program Expert Panel
Report, and British Thoracic Society/Scottish Intercollegiate Guidelines Network [BTS/
SIGN]) have offered a coherent, evidenced-based, stepwise approach for pharmacological
management that can be used within primary and specialist care settings [3–5]. These guide-
lines strongly advocate finding the minimum effective treatment dose that can achieve symp-
tom control. Indifference to this recommendation increases the risk of serious adverse
medication effects because of the chronicity of treatment and unquestionably increases medi-
cation costs. The ongoing improvement in asthma care, alongside a higher disease prevalence
and rapid growth of more expensive newer drugs, has led to ever-increasing total medication
costs across many countries [6–8]. For example, in the UK, asthma costs are over £1.1 billion,
of which around 80% is for drug costs, and in the United States, the cost of asthma is around
$80 billion annually, of which nearly two-thirds is for prescriptions [6].
The GINA 2019 guidelines recommend a paradigm shift in asthma treatment, advising all
asthma patients to receive ICSs, starting with low-dose ICSs or as-needed low-dose ICS–for-
moterol in the GINA guidelines, and escalating as necessary. For the majority of patients,
80%–90% of the therapeutic benefit of ICSs are obtained with low doses [9,10]. Prolonged use
and higher doses of ICS are associated with a progressive risk of systemic adverse effects,
including adrenal suppression, diabetes, cataracts, glaucoma, osteoporosis, and fractures.
Unlike the plateau effect of efficacy outcomes, which occurs with higher ICS doses, there is no
plateau to the risk of adverse effects [11]. Community studies from Australia and Scotland sug-
gest patients are often inappropriately prescribed, and remain on, high doses of ICSs [12,13].
International and national guidelines recommend stepping down treatment once asthma is
controlled to prevent accumulating adverse effects, yet it is thought to be an uncommon prac-
tice [3,14], even though the majority of asthma patients seldom exacerbate [15].
In this study, using nationally representative primary care data from across the UK, we first
evaluated the temporal pattern of preventer prescriptions (prevalent and incident prescrip-
tions), the associated patient characteristics, and the frequency of medication step change. We
then focused on patients that were stepped down to evaluate any associated health and cost
impact.
Methods
Ethical approval
The protocol for this research was approved by the Independent Scientific Advisory Commit-
tee (ISAC) for MHRA Database Research (protocol number 18_120) and is available alongside
the STROBE checklist for observational studies (S1 STROBE Checklist & S1 Study Protocol).
This study is based, in part, on data from the Clinical Practice Research Datalink (CPRD)
obtained under licence from the UK Medicines and Healthcare products Regulatory Agency.
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The data are provided by patients and collected by the National Health Service (NHS) as part
of their care and support. Linked pseudonymised data were provided for this study by CPRD.
Data are linked by NHS Digital, the statutory trusted third party for linking data, using identi-
fiable data held only by NHS Digital. Select general practices consent to this process at a prac-
tice level, with individual patients having the right to opt-out. The Office for National Statistics
(ONS) was the provider of the ONS data contained within the CPRD data. The interpretation
and conclusions contained in this study are those of the authors alone.
Data sources
We used the CPRD-GOLD, a nationally representative database of deidentified UK primary
care electronic medical records. CPRD holds information on diagnoses, symptoms, and pre-
scriptions on more than 11 million patients [16]. It is one of the largest longitudinal healthcare
databases worldwide and has been validated extensively [16]. Secondary care information was
obtained from the Hospital Episode Statistics (HES) database. HES only covers English NHS
hospitals, so around 60% of CPRD practices have individual level HES linkage, socioeconomic
data (using the Index of Multiple Deprivation), and mortality data (ONS).
In the UK, each single inhaler prescribed should last one month if taken as per manufac-
turer intended dose (usually as 2 puffs twice a day). A new prescription is recorded for every
successive inhaler, and more than one of the same inhaler can be prescribed on the same day
(and is recorded as such).
Study populations and design
Main study population. Inclusion criteria were an asthma diagnosis using a validated
algorithm of including asthma clinical codes (with an 86% positive predictive value) [17], no
chronic obstructive pulmonary disease (COPD) co-diagnosis [18],�18 years old, and�1 year
of prescription data (Fig 1 & Fig 2). Prescription data were considered eligible for study inclu-
sion (‘eligible prescription date’) from the latest date of the following: January 1st, 2001,
research acceptable date (CPRD quality control), continuous records date, 18th birthday, or
asthma diagnosis date. Follow-up was censored at the earliest date of the following: January 1st,
2018, date transferred out of CPRD, last data collection, or death.
Prescription analysis (prevalent and incident prescriptions). To be eligible, patients
had to have�1 year of follow-up and�3 preventer prescriptions (Figs 1 & S1). For the inci-
dent (first asthma prescription) analysis, patients were included if they had�2 asthma pre-
scriptions within the year after their incident prescription (to exclude patients prescribed a
‘trial’ inhaler; in the UK, trialling an inhaler is often part of the diagnostic pathway to deter-
mine whether a patient has asthma or not),�1 year of no preventer prescriptions before their
incident prescription, and were HES-linked. Patients characteristics in the incident analysis
were described to assess their suitability for their level of inhaler and their potential risk of
medication adverse effects. A change in prescriptions was described using the 2016 SIGN/BTS
stepwise approach [3].
Stepping-down outcomes analysis. To determine the health impact, a cohort of regular
preventer users was drawn from the main study population (Fig 1 & S1 Fig). Exposed patients
had asthma medication stepped down, and unexposed patients were all other eligible patients.
Patients could only enter this cohort once they had been prescribed�3 ICSs during a 1-year
period after their eligible prescription date and were HES-linked. This cutoff was chosen to
include patients with regular inhaler use, potentially suitable for reduction in their treatment
level. The ‘step-down date’ was defined as either the date of stepping down (exposed patients)
PLOS MEDICINE Health and cost impact of stepping down asthma medication
PLOS Medicine | https://doi.org/10.1371/journal.pmed.1003145 July 21, 2020 4 / 19
Fig 1. Study design. COPD, chronic obstructive pulmonary disease; CPRD, Clinical Practice Research Datalink; HES,
Hospital Episode Statistics; ICS, inhaled corticosteroid
https://doi.org/10.1371/journal.pmed.1003145.g001
Fig 2. Flow diagram for study. CPRD, Clinical Practice Research Datalink; ICS, inhaled corticosteroid
https://doi.org/10.1371/journal.pmed.1003145.g002
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or, if unexposed, the first date after satisfying all eligibility criteria. This cohort was also used to
determine the prognostic factors associated with instigating stepping down.
The ‘index date’ for the outcome analysis was then recorded as 2 months from the stepdown
date. This time period was set because although a single inhaler prescription should last 1
month, many patients miss doses. In this cohort, patients received a mean of 7 prescriptions
per year (IQR 6–9), suggesting each inhaler was used on average for approximately 2 months.
Therefore, after this time period, patients were considered to be no longer using their dropped
medication; however, a sensitivity analysis was also carried out assuming 1- and 3-month time
periods.
Stepping down and medication escalation
Stepping down was based on guideline recommendations and was defined as (1) dropping an
add-on therapy (LABA, leukotriene receptor antagonist [LTRA], theophylline, or long-acting
muscarinic antagonist [LAMA]), (2) halving the ICS inhaler dose (for example, beclometasone
200 mcg to 100 mcg), or (3) halving the mean-daily ICS dose (stepping down by reducing
daily inhalations) [3,4]. Most ICS stepping-down trials used a 50% stepdown [19]; using a
lower stepdown would be less likely to identify an effect if there is one. To be included, patients
had to have�3 inhalers of the stepped-down drug in the year before stepping down. Only the
first stepdown that occurred during follow-up was included.
A drop in mean-daily ICS was measured by comparing the mean ICS dose per day in 1 year
with the mean ICS dose per day in the first 4 months of the subsequent year (‘assessment
year’). The first day of the assessment year was recorded as the index date.
Escalation was defined as the opposite of stepping down (i.e., addition of an add-on therapy
or doubling of ICS dose) occurring in the year following the index date.
Outcomes and confounders
The primary outcome was asthma exacerbations. These were identified as previously defined
[20], as a short course of oral corticosteroids, an emergency department visit for asthma, a hos-
pital admission, or death secondary to asthma. An exacerbation had to occur within 12 months
of the patient’s study entry date. The secondary outcome was a change in reliever prescrip-
tions. This was defined as an increase of�1 reliever prescription (short-acting beta-agonist) in
the year after the index date compared with the year before. Frequency of SABA is used to help
assess asthma control and is often used in observational studies as a proxy for asthma control
[21–24]. A history of atopy, gastroesophageal reflux, smoking, anxiety, depression, cataracts,
pneumonia, diabetes, osteopenia, osteoporosis, and arrhythmia was recorded using appropri-
ate Read codes (see S1 CPRD_medcodes). Variables defined only using data from the year
prior to the index date were ‘ICS stability’ (binary variable; defined as change or no change in
ICS inhaler prescription dose or type), ‘maximum ICS dose’ (categorical variable [low,
medium, or high]); maximum dose of ICS prescription), ‘ICS frequency’ (categorical variable
(0–3, 4–6, 7–10,�11); number of ICS prescriptions) and reliever frequency (binary variable
(<3,�3); number of short-acting beta-agonist canisters). Also, using only data from the previ-
ous year, nonpharmacological management was assessed using appropriate Read codes for the
occurrence of the following within primary care: patient given an asthma management plan,
annual asthma review, or inhaler technique check. Patients prescribed LABA–ICS were cate-
gorised by combination inhaler or not (this variable was included as a secondary analysis, after
a reviewer’s suggestion). ICS dose was categorised using the 2016 SIGN/BTS guidelines, based
on fine-dose beclometasone dipropionate equivalent: low dose (�799 mcg), medium dose
(800–1,599 mcg), and high dose (�1,600 mcg) [3]. The cutoff for an infrequent ICS
PLOS MEDICINE Health and cost impact of stepping down asthma medication
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prescription was defined as�2 prescriptions per year, based on the distribution across the
whole cohort.
Statistical analysis
For prevalent prescriptions, the maximum therapy level per patient each calendar year was
determined. To evaluate change in prescriptions from the first (incident) preventer medication
prescribed, a single prescription increase/decrease during a patient’s total follow-up was
recorded as a change. The effect of stepping down on exacerbations was analysed in an inten-
tion-to-treat Cox proportional hazards model adjusted for sex, age, body mass index (BMI),
smoking, socioeconomic class, gastroesophageal reflux, anxiety, depression, annual asthma
review, inhaler technique check, asthma management plan, exacerbations, reliever use, maxi-
mum ICS dose, ICS frequency, ICS stability, and add-on therapies using complete case analy-
sis. Patients were censored on their first exacerbation or 1 year after the index date. Schoenfeld
residuals were found not to violate the proportional hazards assumption [25]. The effect of
stepping down on reliever use was analysed in an intention-to-treat logistic regression model
adjusted for the same variables as the Cox model. The association between potential prognostic
factors and initiating stepdown was assessed using multivariable mixed-effects logistic regres-
sion models, using GP practice as the random intercept. Several sensitivity and subgroup anal-
yses were performed (1) using a 6-month (instead of 12-month) outcome window after the
index date, (2) defining the date of stepping down at 1 month and at 3 months after the last
prescription date (instead of 2 months), (3) stratifying patients by presence of exacerbations in
the year prior to the index date, and (4) analysing the effect on exacerbations using an as-
treated approach (censoring stepped-down patients on date of escalation, if within 1 year of
the index date). To further diminish the effect of selection bias, an additional analysis using
inverse-probability–weighted propensity score methodology was used; the average treatment
time for the first exacerbation was compared between each stepdown and no stepdown. All
statistical analyses were performed using STATA 14.2.
Cost analysis
Cost analyses for the cohort were performed applying drug costs alone. Price per drug was
obtained using 2019 indicative prices from the NHS Dictionary of Medicines and Devices to
avoid a cost effect due to price changes [26]. Patients prescribed drugs that no longer had a
price available were excluded. Individual cost differences were calculated by subtracting the cost
of preventer medications prescribed 12 months post-index date from the yearly drug costs pre-
index date. The mean of those differences was calculated for the cohort by medication stepped
down. The mean cohort costs were used to estimate population-level costs for stepping down
LABAs or ICSs using the following assumptions: UK population was 65 million, of whom 80%
were adults (based on 2019 ONS data); 7% had asthma [27]; 50% were prescribed LABAs; 40%
were prescribed medium- or high-dose ICSs (Fig 1); 15% had a ‘stable’ year; and only half of the
eligible population were stepped down (Table 1). A ‘stable’ year was defined as�3 ICS prescrip-
tions, no change in preventer medications, or<3 reliever prescriptions and no exacerbations.
Results
Prevalent preventer prescriptions
508,459 patients were identified; the proportion on higher-level preventer medications
(medium/high-dose ICSs or ICSs and add-on therapy) steadily increased over time
(2001 = 49.8%, 2017 = 68.3%; Fig 3).
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In 2017, only 31.7% of patients were treated with low-dose ICSs alone. Most patients were
managed with ICSs and 1 add-on. Of those prescribed an add-on, 88.3% were prescribed a
combination LABA–ICS inhaler, of which 69.6% included medium- or high-dose ICSs.
First-time (incident) preventer prescriptions
107,908 patients were identified for the incident analysis; around one-third were prescribed
higher-level medication as their first asthma preventer medication (S1 Fig). Most patients pre-
scribed an add-on were prescribed LABAs (94.0%), of whom 74.6% were prescribed either
medium- or high-dose ICSs. Of those prescribed LABA–ICS, 77.2% were prescribed an
LABA–ICS combination inhaler throughout the time period, but by 2016 onwards, all LABA–
ICS prescriptions were combination inhalers.
In patients prescribed ICSs + 1 add-on, 70.4% did not have their prescription changed dur-
ing a mean follow-up of 6.6 years (Table 1). Of those prescribed medium- or high-dose ICSs,
54.5% kept the same therapy or escalated during a mean follow-up of 8.1 years.
Of those prescribed higher-level medication as their incident asthma prescription (all steps
above low-dose ICSs), 48.4% had no exacerbation or reliever prescriptions in the previous
year. The median time since diagnosis before first prescription was 19.2 months, and 13.2%
already had a comorbidity that could be worsened by corticosteroids (S1 Table).
Of those prescribed medium- or high-dose ICSs as their incident prescription, 13.0% had
known diabetes, cataracts, glaucoma, osteopenia, or osteoporosis at the time of prescription,
compared with 11.2% prescribed incident low-dose ICSs (Table 2).
Table 1. Change of preventer medication during follow-up from incident prescription.
Mean Follow-up (95% CI) No Change (%) Escalate Only (%) Stepdown Only (%) Escalate and Stepdown (%)
Low-dose ICSs 6.6 years (6.5–6.6) 41.7 39.5 � 18.9
Medium/high-dose ICSs 8.1 years (8.0–8.2) 19.5 34.3 14.5 31.7
ICSs + 1 add-on 6.6 years (6.6–6.7) 70.4 6.3 7.8 15.5
�Patients that stopped all preventer medications were not included. Abbreviations: ICS, inhaled corticosteroid.
https://doi.org/10.1371/journal.pmed.1003145.t001
Fig 3. Prevalent asthma preventer prescriptions from across the UK, 2001–2017. The light blue area below the
dotted line is the percentage of patients prescribed medium-dose or high-dose ICSs that are prescribed an ICS and 1
add-on therapy. Add-on therapy refers to LABA, LTRA, theophylline, or LAMA. ICS, inhaled corticosteroid; LABA,
long-acting β2-agonist; LAMA, long-acting muscarinic antagonist; LTRA, leukotriene receptor antagonist.
https://doi.org/10.1371/journal.pmed.1003145.g003
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Effect of stepping down on exacerbations
125,341 patients (mean age 50.4 years, 39.4% males) satisfied the criteria for the stepping-
down analysis: 39,881 were stepped down (ICS mean daily = 26,603, ICS inhaler dose = 6,182,
LABA = 4,078, other add-on = 3,018), and 85,460 were not stepped down (Table 3).
Stepping down LABA or other add-on medication or ICSs, either by reducing the dose of
the inhaler or by reducing the number of puffs, did not significantly increase the risk of an
exacerbation in the subsequent year (adjusted hazard ratio, 95% CI, p-value: ICS inhaler
dose = 0.86, 0.77–0.93, p< 0.001; ICS mean daily = 0.80, 0.74–0.87, p< 0.001; LABA = 0.99,
0.92–1.11, p = 0.87; other add-on = 0.99, 0.91–1.09, p = 0.79; Table 4). The main findings
remained robust in the sensitivity analyses (S2 Table). The stratified analysis by prior exacerba-
tion history showed no significant difference (S3 Table). The treatment effect analysis found
negligible difference in days between first exacerbation in patients with stepped-down drug
and no stepdown (S4 Table).
The proportion of unexposed patients that had treatment escalated in the year following the
index date was similar to or higher than that for mean-daily ICS or LABA (unexposed = 16.7%
[95% CI 16.3–17.0], mean-daily ICS = 16.3% [95% CI 15.8–16.7]; LABA = 11.0% [95% CI
10.1–12.0]; S5 Table). Patients that dropped their ICS inhaler dose, LTRA, LAMA, or theoph-
ylline had higher proportions escalate (ICS inhaler dose = 29.5% [95% CI 28.3–30.7],
LTRA = 20.5% [95% CI 18.7–22.4], LAMA = 23.2% [95% CI 20.0–26.5], theophylline = 59.8%
[95% CI 55.9–63.7]).
Table 2. Patient characteristics at their first asthma preventer prescription by ICS dose prescribed; low-dose ICSs
compared with medium/high-dose ICSs.
Low-Dose ICSs Incident
Prescription
Medium/High-Dose ICSs Incident
Prescription
Median (IQR) Median (IQR)
Age (years) 48 (35–62) 52 (39–64)
Reliever frequency 1 (0–2) 0 (0–1)
N (%) N (%)
Total 68,363 (100%) 39,545 (100%)
Never smoked 22,727 (33.2%) 12,186 (30.8%)
Atopy 32,314 (47.3%) 18,544 (46.9%)
Anxiety 13,016 (19.0%) 7,455 (18.9%)
Reflux 6,993 (10.2%) 4,746 (12.0%)
Bronchiectasis 306 (0.4%) 418 (1.1%)
GP-treated exacerbations 7,666 (11.2%) 5,379 (13.6%)
Hospital exacerbations 883 (1.3%) 885 (2.2%)
IHD 3,181 (4.7%) 2,502 (6.3%)
Hypertension 14,211 (20.8%) 9,073 (22.9%)
Arrhythmia 2,021 (3.0%) 1,536 (3.9%)
Pneumonia 1,812 (2.7%) 1,332 (3.4%)
Comorbidity that could be worsened by
corticosteroids
7,674 (11.2%) 5,128 (13.0%)
Glaucoma 862 (1.3%) 639 (1.6%)
Cataracts 2,125 (3.1%) 1,419 (3.6%)
Osteopenia/osteoporosis 1,960 (2.9%) 1,337 (3.4%)
Diabetes 3,875 (5.7%) 2,498 (6.3%)
Abbreviations: GP, general practitioner; ICS, inhaled corticosteroid; IHD, ischaemic heart disease.
https://doi.org/10.1371/journal.pmed.1003145.t002
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Table 3. Patient characteristics of each exposed and unexposed group.
Characteristics Controls/Unexposed Stepped-Down Drug
Not Stepped Down ICSs LABA Other Add-on
N % N % N % N %
Total 85,460 100.0 32,785 100.0 4,078 100.0 3,018 100.0
ICS stepdown
Mean-daily ICS – – 26,603 81.1 – – – –
Inhaler dose – – 6,182 18.9 – – – –
Other add-on
LTRA – – . . – – 1,751 58.0
Theophylline – – . . – – 605 20.0
LAMA – – . . – – 662 21.9
Age
18–29 10,936 12.8 4,503 13.7 522 12.8 273 9.0
30–40 13,303 15.6 5,899 18.0 610 15.0 418 13.9
40–50 16,403 19.2 6,984 21.3 710 17.4 594 19.7
50–60 14,603 17.1 5,691 17.4 661 16.2 624 20.7
60–70 14,367 16.8 4,817 14.7 673 16.5 537 17.8
�70 15,848 18.5 4,891 14.9 902 22.1 572 19.0
Males 34,100 39.9 13,049 39.8 1,465 35.9 1,020 33.8
Socioeconomic status
1 (least deprived) 13,920 16.3 4,884 14.9 637 15.6 411 13.6
2 16,347 19.1 6,555 20.0 811 19.9 593 19.6
3 16,154 18.9 6,565 20.0 779 19.1 539 17.9
4 18,041 21.1 7,191 21.9 881 21.6 632 20.9
5 20,998 24.6 7,590 23.2 970 23.8 843 27.9
BMI
Normal 18,120 23.0 7,350 24.0 873 22.7 630 21.9
Underweight 1,659 2.1 608 2.0 86 2.2 59 2.1
Overweight 32,929 41.8 12,802 41.8 1,544 40.2 1,157 40.3
Obese 26,163 33.2 9,876 32.2 1,335 34.8 1,026 35.7
Smoking history
Never 27,822 32.6 10,799 32.9 1,264 31.0 967 32.0
Current 28,452 33.3 11,383 34.7 1,359 33.3 970 32.1
Ex-smoker 29,186 34.2 10,603 32.3 1,455 35.7 1,081 35.8
Atopy 46,104 53.9 17,917 54.6 2,283 56.0 1,842 61.0
Anxiety 18,836 22.0 6,816 20.8 1,031 25.3 777 25.7
Depression 22,921 26.8 8,582 26.2 1,227 30.1 946 31.3
Reflux 11,787 13.8 4,151 12.7 717 17.6 571 18.9
In year prior to exposure
�1 exacerbation 8,204 9.6 2,750 8.4 526 12.9 585 19.4
ICS frequency
3 18,328 21.4 6,582 20.1 937 23.0 350 11.6
4–6 37,611 44.0 17,467 53.3 1,924 47.2 1,123 37.2
7–10 19,439 22.7 6,410 19.6 833 20.4 930 30.8
�11 10,082 11.8 2,326 7.1 384 9.4 615 20.4
Max ICS
Low dose 48,136 56.3 16,266 49.6 1,647 40.4 937 31.0
Medium dose 26,969 31.6 11,295 34.5 1,669 40.9 1,010 33.5
(Continued)
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Effect on reliever use
Stepping down was not associated with an increase in reliever use (adjusted odds ratio [95%
CI, p-value]: ICS inhaler dose = 0.99 [0.98–1.00, p = 0.59], ICS mean daily = 0.78 [0.76–0.79,
p< 0.001], LABA = 0.83 [0.82–0.85, p< 0.001], other add-on = 0.86 [0.85–0.87, p< 0.001];
Table 5).
Prognostic factors for initiating stepping down
The factors significantly associated with initiating ICS stepdown included high- or medium-
dose ICSs,�4 ICS prescriptions, current smoker, LABA use, and ICS stability (S6 Table).
Table 3. (Continued)
Characteristics Controls/Unexposed Stepped-Down Drug
Not Stepped Down ICSs LABA Other Add-on
N % N % N % N %
High dose 10,355 12.1 5,224 15.9 762 18.7 1,071 35.5
Stable ICS 68,671 80.4 26,300 80.2 2,875 70.5 2,242 74.3
LABA use 46,256 54.1 15,464 47.2 0 0.0 2,478 82.1
�2 add-on therapies 686 0.8 185 0.6 23 0.6 528 17.5
Reliever frequency
0–2 27,764 32.5 12,094 36.9 1,560 38.3 809 26.8
3–7 36,874 43.1 15,077 46.0 1,770 43.4 1,177 39.0
�8 20,822 24.4 5,614 17.1 748 18.3 1,032 34.2
Annual asthma review 45,893 53.7 15,775 48.1 2,136 52.4 1,558 51.6
Inhaler technique 37,633 44.0 13,517 41.2 1,807 44.3 1,246 41.3
Asthma management plan 9,673 11.3 3,080 9.4 479 11.7 297 9.8
Dashes indicate no data/not applicable. Abbreviations: BMI, body mass index; ICS, inhaled corticosteroid; LABA, long-acting β2-agonist; LAMA, long-acting
muscarinic antagonist.
https://doi.org/10.1371/journal.pmed.1003145.t003
Table 4. Risk of an exacerbation by medication stepped down.
Adjusted HR 95% CI p-Value
Drug stepped down
None Reference
ICS: inhaler dose 0.86 0.77–0.93 <0.001
ICS: mean daily 0.80 0.74–0.87 <0.001
LABA 0.99 0.92–1.11 0.871
Other add-on 0.99 0.91–1.09 0.791
Cox proportional hazard regression was used to assess the association between an exacerbation in the year after each
stepdown, compared with no stepdown, after adjusting for sex, age, BMI, smoking history, socioeconomic status,
atopy, anxiety, depression, gastroesophageal reflux, and in the year prior to exposure: maximum ICS dose, ICS
stability, ICS frequency, reliever frequency, LABA use, at least 2 add-on therapies, exacerbations, annual asthma
review, inhaler technique check, and asthma management plan. The rate and number of exacerbations (per 10 person
years, N) of patients that had an exacerbation by drug stepped down were none (1.23 per 10 person years, N = 9,984),
ICS mean daily (0.84 per 10 person years, N = 2,163), ICS inhaler dose (1.13 per 10 person years, N = 720), LABA
(1.18 per 10 person years, N = 458), other add-on (2.02 per 10 person years, N = 564). Abbreviations: BMI, body
mass index; HR, hazard ratio; ICS, inhaled corticosteroid; LABA, long-acting beta-agonist.
https://doi.org/10.1371/journal.pmed.1003145.t004
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Common ICS side effects, diabetes, and cataracts were not associated with initiating stepdown,
but osteopenia/osteoporosis was significantly associated with not stepping down. Combina-
tion LABA–ICS use, an annual asthma review, past exacerbation, and being older were also
significantly associated with not initiating ICS stepdown.
The factors significantly associated with stepping down add-on therapy included using�2
add-on therapies, LABA, past exacerbation, high-dose ICSs, older age, ICS stability, history of
pneumonia, or arrhythmia (S6 Table).
Cost savings
In the cohort of regular inhaler users, 31,379 patients were stepped down and had available
drug costs in 2019. The mean annual saving was highest for LAMAs and LABAs and lowest for
ICSs (ICS = £60.30 [95% CI 59.34–61.27], LABA = £126.92 [95% CI 123.61–130.22], LTRA =
£108.86 [103.91–113.82], LAMA = £150.38 [139.65–161.12], theophylline = £114.98 [105.12–
123.67]), S7 Table. Using the assumptions described in the methods, estimated UK savings
from stepping down LABAs from half of the UK’s stable adults treated with LABA–ICS would
result in around 340,000 people having 7 fewer preventer prescriptions per year, saving
approximately £17,000,000 annually. The equivalent calculations if stepping down ICSs would
save around £8,600,000.
Discussion
In a representative UK general asthma cohort, we have shown that between 2001 and 2017,
prescription of higher-level preventer medications became increasingly common. There was
often no clear clinical requirement for such high doses; one-third of patients had not received
a reliever inhaler prior to their first asthma prescription or had an exacerbation. Nearly three-
quarters of patients who were prescribed an ICS + 1 add-on as their first medication remained
on the same medication for several years. One in 8 patients who were prescribed a medium/
high-dose ICS as their first preventer already had known steroid-induced adverse effects.
When medication stepdown was initiated, it was found to be safe, with no increase in exacer-
bations or reliever use, and economical.
Table 5. Risk of increase in reliever use by medication stepped down.
Adjusted OR 95% CI p-Value
Drug stepped down
None Reference
ICS: inhaler dose 0.99 0.98–1.00 0.594
ICS: mean daily 0.78 0.76–0.79 <0.001
LABA 0.83 0.82–0.85 <0.001
Other add-on 0.86 0.85–0.87 <0.001
Logistic regression analysis was used to assess the association between an increase of one or more reliever inhaler
prescription in the year after each stepdown, compared to no stepdown, after adjusting for sex, age, BMI, smoking
history, socioeconomic status, atopy, anxiety, depression, gastroesophageal reflux, and in the year prior to exposure:
maximum ICS dose, ICS stability, ICS frequency, reliever frequency, LABA use, at least 2 add-on therapies,
exacerbations, annual asthma review, inhaler technique check, and asthma management plan. The number of
patients that had an increase in reliever by drug stepped down was none (N = 19,027, 22.3%), ICS inhaler dose
(N = 2,447, 39.6%), LABA (N = 1,269, 31.1%), other add-on (N = 832, 27.3%). Abbreviations: BMI, body mass index;
ICS, inhaled corticosteroid; LABA, long-acting β2-agonist.
https://doi.org/10.1371/journal.pmed.1003145.t005
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In over 0.5 million asthma patients, the proportion prescribed higher-level medications
(medium-dose ICSs, high-dose ICSs, or fixed-dose ICSs with add-on therapy) steadily
increased over the past 2 decades. By 2017, only one-third of patients were managed on low-
dose ICSs alone, in keeping with older UK studies also suggestive of inappropriate prescribing
of higher doses of ICSs [28,29]. This pattern may have occurred because firstly, there was a rel-
atively high number of patients, around one-third, who were prescribed their first preventer
medication above the initial preventer step recommended by guidelines. Secondly, a high pro-
portion of patients either remained on their incident prescription or had their medication
escalated but never stepped down thereafter (including 77% of those prescribed ICSs + 1 add-
on). Patients often have treatment stepped up in response to temporary worsening control or
an acute exacerbation, but once control is achieved, their medication is not reviewed again
[14]. Our study found most patients receiving a higher-level preventer medication as their first
asthma medication had not received a prescription for a preventer inhaler in the previous year
(guidelines pre-2016 advised reliever therapy alone as the first treatment step [30]) nor experi-
enced an exacerbation. The prescribing of a higher level of medication without clear clinical
indication suggests the prescribing physicians were not following guideline recommendations.
This is perhaps not a surprising finding because adherence to guidelines in general practice
has been shown to be low in many countries [28,29,31–34].
Physicians prescribing higher ICS doses were perhaps also not alert to potential adverse sys-
temic effects because 13% of those prescribed medium- or high-dose ICSs as their first pre-
scription already had known relevant comorbid conditions (i.e., diabetes, cataracts, glaucoma,
osteopenia, or osteoporosis) compared with 11% of those prescribed low-dose ICSs. The
majority of patients prescribed ICSs and an add-on were prescribed a fixed daily medium-
dose or high-dose ICS–LABA combination inhaler. The latest recommendation in GINA for
mild and moderate asthma, supported by multiple recent randomised control trials (RCTs)
[35–38], is a low-dose ICS-containing inhaler. These latest guidelines should help encourage
health professionals to prescribe the minimally effective treatment dose. Furthermore, for
most patients, 80%–90% of the therapeutic benefit has been found to occur with low-dose ICSs
[9,10].
The most common form of stepdown was halving ICS inhalations, a pragmatic approach
that can be readily instigated by patients with or without direction from healthcare profession-
als. Stepdown did not significantly increase the risk of exacerbations, regardless of which med-
ication was stepped down. Interestingly, there was a slight reduction in exacerbations when
stepping down ICSs not seen when stepping down add-on therapies. This could be explained
by confounding by indication from an unmeasured variable that led to patient selection only
in patients with ICS overtreatment or could be due to increased adherence after medication
change from increased medication awareness [39].
Findings remained robust even after all sensitivity analyses. As may be expected, the biggest
positive confounding effect was a history of exacerbations in the year prior [15], but even
when stratifying by this parameter, there was still no observed increase in exacerbations. This
could be explained by patient selection towards the most stable patients, even those that had
exacerbated. Another possibility is that this may reflect poor inhaler technique such that step-
ping down prescriptions did not significantly alter the absorbed dose. Considering stepping
down is arguably still important in patients with low medication absorption (from either low
adherence or poor technique) in terms of both reducing medication costs and alerting patients
and physicians to these potential issues. Lastly, it is likely some patients were misdiagnosed
[40], and routinely thinking about stepping down medication (as well as stepping up) as part
of an annual asthma review could help identify such patients.
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A Cochrane Review, 2017, looked at studies that stepped down ICSs in well-controlled
asthma patients [19]. The review found 6 relevant studies; there was no difference in asthma
exacerbations, asthma control, side effects, or quality of life. However, the quality of evidence
was rated as low or very low. A Cochrane Review, 2015 [41], looked at studies that stopped
LABA in well-controlled adults. Five studies were reviewed, with moderate quality of evidence.
However, trials were short, with too few exacerbations to assess rates [41]. A small study pub-
lished since found stopping LABAs was well tolerated [42].
There has only been one previous real-world study comparing stepped-down patients to
controls. Using US administrative claims data, the authors identified a smaller cohort of 4,235
eligible patients with a shorter follow-up period and no exact timing of stepdown; this study
found stepping down to be safe and highly cost-effective [43].
Around 1 in 6 controls had their treatment escalated in the year after the index date; this
number was comparable to those that stepped down their ICS inhalations or their LABAs. A
slightly higher number, around 1 in 5, escalated treatment if they had dropped LTRAs,
LAMAs, or the ICS inhaler dose. Stepping down did not significantly increase the use of
reliever medication, and most patients did not escalate treatment more than the controls;
together, these findings suggest stepping down did not have a detrimental effect on patient’s
asthma control.
Although the reason for stepping down was not recorded, we were able to evaluate several
potential prognostic factors. We found higher levels of medication and prescription stability
were associated with instigating stepping down. Use of combination inhalers was associated
with reduced odds of stepping down ICSs; however, this is likely to change with the latest
GINA guidelines encouraging an as-needed approach. In contrast, common ICS adverse sys-
temic effects, diabetes, cataracts, glaucoma, osteopenia, or osteoporosis were not associated
with stepping down ICS. Older age was significantly associated with not having ICSs stepped
down but was significantly associated with stepping down LABAs. Yet the older population
are at the greatest risk of ICS side effects and are most likely to experience polypharmacy. In
the UK, older people have a similar prevalence of asthma as younger adults but are the age
group most likely to be prescribed ICSs and most likely to be prescribed medium- or high-
dose ICSs instead [27]. It seems that age is a barrier to instigating stepping down, but our anal-
ysis found older age did not impact on asthma outcomes. Recently, there has been a drive in
older people to rationalise medicines through deprescribing, and patients are keen to engage
[44–46]. Notably, asthma-specific clinical practices, including annual reviews and manage-
ment plans, did not appear to increase the chances of stepping down. A qualitative study of
primary care health professionals suggested that key factors why stepping down does not
occur are lack of confidence to step down, lack of time to discuss, and resistance from the
patients [47].
Our cost analysis found considerable savings covering during just 1 year. The savings from
dropping LABAs were almost 4 times that of ICSs and approximately double that of LTRAs.
Scaling up the costs to estimate nationwide savings, assuming only half of all stable treated
patients are stepped down, could potentially save around £17 million if LABAs were stepped
down, equivalent to 2% of the UK’s asthma budget, or £8.6 million if ICSs were stepped down.
This large sum is because over 5.4 million people receive asthma treatment in the UK, with
asthma medication contributing towards 13% of the total primary care prescribing costs [48]
and ICSs being the second most prescribed medication [49]. Many patients prescribed higher
doses have suboptimal inhaler technique, and hence, only a small proportion reaches the air-
ways; the money saved on stepping down could instead be spent on improving and adapting
education tools for patients and professionals, for example, to cover the continuously expand-
ing inhaler market [50–52].
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Strengths and limitations
Major strengths were the use of a nationally representative study population, large sample size,
and longevity of the data. Limitations of using routinely collected patient data include lack of
information on daily medication use; therefore, to include patients who reduced the number
of puffs, we had to calculate mean-daily ICS doses. This could have led to selection bias by
excluding patients who decreased, then increased, their puffs again. However, our findings in
this group were consistent with patients that had their ICS inhaler dose halved, suggesting this
bias had a minimal influence on the effect estimate. It is possible there was selection bias from
only including HES-linked patients in the stepping-down analysis because HES is only avail-
able for patients using English NHS hospitals. The nature of the data also did not allow us to
know precisely why the decision to initiate stepdown was taken; hence, our analysis of poten-
tial prognostic factors attempted to investigate this. Although the algorithm used to identify
asthma patients has 86% positive predictive value [17], a limitation of the data set is that it does
not contain information on diagnostic tests such as lung function tests or airway hyperreactiv-
ity measures. Only around 4% of asthma patients are reviewed in secondary care, where such
tests are performed in the UK [53]. Mild exacerbations treated only with an increase in ICSs
could not be identified, but an annual increase in preventers and relievers was measured.
Additionally, prescriptions in the exposed and unexposed may not have been dispensed or
adhered to; however, our findings were comparable to the only other study using real-world
data, which had access to dispensed data. Lastly, although guidelines suggest stepping down
after 3 months of stability, 1 year of stability was used for the cost analysis; therefore, results
may be more conservative than would truly occur.
Conclusions
Over time, patients in the UK have been increasingly prescribed higher-level asthma medica-
tions with no clear clinical indication for needing higher doses. Worryingly, although stepping
down of treatment is recommended by clinical guidelines, we found that it happened infre-
quently. Stepping down ICSs or add-on therapy did not appear to worsen health outcomes but
did appear to result in significant cost savings. Medication burden seemed to be the main
driver to stepping down; adverse medication effects were not. In summary, firstly, adverse
treatment effects, medication burden, and cost to the health system should be considered
when prescribing higher-level asthma medications for well-controlled asthma patients seen in
primary care. Secondly, stepping down medication in stable asthma patients appears to be
both safe and highly cost-effective.
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